Iadademstat, Atezolizumab, DurvalumabTesting the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Sponsor:

National Cancer Institute (NCI)

Code:

NCT06287775

Conditions

Extensive Stage Lung Small Cell Carcinoma

Stage IV Lung Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atezolizumab

Biopsy Procedure

Biospecimen Collection

Computed Tomography

Durvalumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2026-08-06.